125 related articles for article (PubMed ID: 37732622)
21. Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
Tang M; Gao S; Zhang L; Liu B; Li J; Wang Z; Zhang W
Prostate; 2020 Jul; 80(10):742-752. PubMed ID: 32449811
[TBL] [Abstract][Full Text] [Related]
22. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
23. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
[TBL] [Abstract][Full Text] [Related]
24. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
25. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling.
Huang SH; Tseng JC; Lin CY; Kuo YY; Wang BJ; Kao YH; Muller CJF; Joubert E; Chuu CP
Phytomedicine; 2019 Nov; 64():153068. PubMed ID: 31419729
[TBL] [Abstract][Full Text] [Related]
26. Dual Akt and Bcl-2 inhibition induces cell-type specific modulation of apoptotic and autophagic signaling in castration resistant prostate cancer cell lines.
Avsar Abdik E; Abdik H; Turan D; Sahin F; Berger MR; Kaleagasioglu F
Mol Biol Rep; 2021 Dec; 48(12):7755-7765. PubMed ID: 34647221
[TBL] [Abstract][Full Text] [Related]
27. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
28. HMGB1 induces radioresistance through PI3K/AKT/ATM pathway in esophageal squamous cell carcinoma.
Zhang X; Zou N; Deng W; Song C; Yan K; Shen W; Zhu S
Mol Biol Rep; 2022 Dec; 49(12):11933-11945. PubMed ID: 36260180
[TBL] [Abstract][Full Text] [Related]
29. ATM deficiency promotes progression of CRPC by enhancing Warburg effect.
Xu L; Ma E; Zeng T; Zhao R; Tao Y; Chen X; Groth J; Liang C; Hu H; Huang J
Endocr Relat Cancer; 2019 Jan; 26(1):59-71. PubMed ID: 30400006
[TBL] [Abstract][Full Text] [Related]
30. ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer.
Wang Z; Zhang X; Li W; Su Q; Huang Z; Zhang X; Chen H; Mo C; Huang B; Ou W; Chen J; Zhao G; Chen L; Shao L
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301812
[TBL] [Abstract][Full Text] [Related]
31. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
Song YM; Qian XL; Xia XQ; Li YQ; Sun YY; Jia YM; Wang J; Xue HQ; Gao GS; Wang XZ; Zhang XM; Guo XJ
Breast Cancer Res Treat; 2022 Nov; 196(1):45-56. PubMed ID: 36056297
[TBL] [Abstract][Full Text] [Related]
32. MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity.
Wang Y; Shao N; Mao X; Zhu M; Fan W; Shen Z; Xiao R; Wang C; Bao W; Xu X; Yang C; Dong J; Yu D; Wu Y; Zhu C; Wen L; Lu X; Lu YJ; Feng N
Oncotarget; 2016 Jul; 7(30):47444-47464. PubMed ID: 27329728
[TBL] [Abstract][Full Text] [Related]
33. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
34. Oxidized ATM promotes abnormal proliferation of breast CAFs through maintaining intracellular redox homeostasis and activating the PI3K-AKT, MEK-ERK, and Wnt-β-catenin signaling pathways.
Tang S; Hou Y; Zhang H; Tu G; Yang L; Sun Y; Lang L; Tang X; Du YE; Zhou M; Yu T; Xu L; Wen S; Liu C; Liu M
Cell Cycle; 2015; 14(12):1908-24. PubMed ID: 25970706
[TBL] [Abstract][Full Text] [Related]
35. Ataxia telangiectasia mutated kinase inhibition promotes irradiation-induced PD-L1 expression in tumour-associated macrophages through IFN-I/JAK signalling pathway.
Gao Y; Li Y; Lin Z; Zeng Y; Huang Z; Han L; Zhong Y; Gong Y; Wu Q; Xie C
Immunology; 2023 Feb; 168(2):346-361. PubMed ID: 36326481
[TBL] [Abstract][Full Text] [Related]
36. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
37. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
38. High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals.
Tang M; Sun Y; Huang CP; Chen L; Liu B; You B; Wang Z; Chang C
Cell Death Dis; 2022 Aug; 13(8):746. PubMed ID: 36038573
[TBL] [Abstract][Full Text] [Related]
39. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.
Zhang Z; Hou X; Shao C; Li J; Cheng JX; Kuang S; Ahmad N; Ratliff T; Liu X
Cancer Res; 2014 Nov; 74(22):6635-47. PubMed ID: 25252916
[TBL] [Abstract][Full Text] [Related]
40. Chemokine C-C motif ligand 21 synergized with programmed death-ligand 1 blockade restrains tumor growth.
Chen Q; Yin H; Pu N; Zhang J; Zhao G; Lou W; Wu W
Cancer Sci; 2021 Nov; 112(11):4457-4469. PubMed ID: 34402138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
